Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.

Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K.

Langenbecks Arch Surg. 2013 Feb;398(2):211-20. doi: 10.1007/s00423-012-1034-5. Epub 2012 Dec 7.

PMID:
23224565
2.

Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?

Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Büchler M, Ott K.

Ann Surg Oncol. 2014 May;21(5):1739-48. doi: 10.1245/s10434-013-3462-z. Epub 2014 Jan 14.

PMID:
24419755
3.

Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.

Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M, Siewert JR, Lordick F.

Langenbecks Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27.

PMID:
23269519
4.

[Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].

Li B, Sun L, Wang X, Deng J, Ding X, Wang X, Ke B, Zhang L, Zhang R, Liang H.

Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Feb 25;20(2):207-212. Chinese.

PMID:
28226357
5.
6.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
7.

Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.

Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, Schumacher C.

Ann Surg Oncol. 2012 Jul;19(7):2108-18. doi: 10.1245/s10434-011-2147-8. Epub 2011 Dec 1.

PMID:
22130620
8.

Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.

Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K.

Gastric Cancer. 2015 Apr;18(2):314-25. doi: 10.1007/s10120-014-0367-x. Epub 2014 Apr 11.

PMID:
24722800
9.

Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.

Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D.

World J Surg. 2010 Dec;34(12):2821-9. doi: 10.1007/s00268-010-0783-y.

PMID:
20827475
10.

The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction.

Yuan D, Zhu K, Li K, Yan R, Jia Y, Dang C.

J Surg Oncol. 2014 Sep;110(3):333-40. doi: 10.1002/jso.23651. Epub 2014 May 29.

PMID:
24889121
11.

What to do after R1-resection of adenocarcinomas of the esophagogastric junction?

Gertler R, Richter J, Stecher L, Nitsche U, Feith M.

J Surg Oncol. 2016 Sep;114(4):428-33. doi: 10.1002/jso.24329. Epub 2016 Jun 22.

PMID:
27333949
12.

Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?

Reeh M, Nentwich MF, Asani S, Uzunoglu FG, Bockhorn M, Sauter G, Rösch T, Izbicki JR, Bogoevski D.

J Gastrointest Surg. 2015 Apr;19(4):587-93. doi: 10.1007/s11605-015-2762-y. Epub 2015 Feb 5.

PMID:
25652343
13.

A reliable risk score for stage IV esophagogastric cancer.

Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K.

Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.01.005. Epub 2013 Jan 31.

PMID:
23375470
14.

The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR.

Cancer. 2006 May 15;106(10):2119-27.

15.

Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.

Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, Daiko H, Nishimura M, Katsumata K, Sugiyama Y, Kinoshita T.

Ann Surg Oncol. 2012 Feb;19(2):677-83. doi: 10.1245/s10434-011-1983-x. Epub 2011 Aug 6.

PMID:
21822549
16.

Multidisciplinary approach to esophageal and gastric cancer.

Stein HJ, Sendler A, Fink U, Siewert JR.

Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6. Review.

PMID:
10836011
17.

Individualized surgical strategies for cancer of the esophagogastric junction.

Stein HJ, Feith M, Siewert JR.

Ann Chir Gynaecol. 2000;89(3):191-8. Review.

PMID:
11079787
18.

Downstaging of esophageal cancer after preoperative radiation and chemotherapy.

Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER.

Ann Surg. 1995 Jun;221(6):685-93; discussion 693-5.

19.

Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.

Zhang H, Wang W, Cheng Y, Song Y, Zhu K, Dang C.

World J Surg Oncol. 2013 Jul 13;11:155. doi: 10.1186/1477-7819-11-155.

20.

Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.

von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR.

J Clin Oncol. 2005 Feb 1;23(4):874-9.

PMID:
15681533

Supplemental Content

Support Center